Role Description
The Institute for Clinical and Economic Review (ICER) is looking to expand its team and is seeking a Health Economist to help lead the health technology assessment and economic evaluation activities that serve as the backbone for all our work.
Under the direction of the Senior Vice President for Health Economics, this individual will be responsible for:
-
Managing the development and testing of rigorous economic models to assess the potential costs, cost-effectiveness, and budgetary impact of a wide range of diagnostic, prognostic, therapeutic, and other clinical interventions.
-
Summarizing results, producing key sections of existing reports, and consulting on multiple approaches to implement findings in practice and policy.
Key Responsibilities include:
-
Providing contributions and supervision on multiple complex projects in coordination with ICER teams and collaborators.
-
Collaborating with senior leadership and other ICER experts to develop and communicate guidance regarding methods and policies relevant to economic evaluation.
-
Consulting with external collaborators and internal project teams on the conception, design, specification, and format for presentation of decision-analytic economic models.
-
Educating and providing consultation on health economic methods to research staff, panel and advisory board members, and other interested stakeholders.
-
Contributing to the reputation of ICER by fostering cooperation, integrity, objectivity, responsiveness, and transparency in economic evaluation.
-
Preparing and delivering presentations and relevant reports for the economic component of ICER evidence reviews.
Qualifications
-
A masterβs-level degree or higher (e.g., doctorate) in a relevant discipline such as decision sciences, health economics, operations research, biostatistics, epidemiology, or a related quantitative social science field.
-
Experience in conducting health technology assessments, academic health-economic modeling, or other health-focused economic evaluation work.
-
Outstanding writing capabilities, able to write clearly and cogently without requiring editorial assistance.
-
Substantial experience in the critical evaluation of evidence, including the ability to critique research methods and statistical findings of published economic studies.
-
Accomplished presenting skills with experience conveying complex methods to a variety of audiences.
-
Efficiency, collaboration, candor, openness, results orientation, and a commitment to a consultative approach to decision-making.
Requirements
-
A track record of mentorship of research staff (for Associate Director or Director level).
-
Analytical, consulting, and project management experience.
-
Methodological development within applied health economics or health technology assessment, as evidenced by authorship of high-impact articles in academic journals.
-
Experience with interactive application programming languages (e.g., VisualBasic, Java, ColdFusion) preferred.
-
Experience with other general programming languages useful in decision analysis (e.g., C++, SAS) preferred.
-
The highest levels of personal initiative, attention to detail, and independent work.
-
Excellent organizational as well as written and oral communication skills.
Company Description
ICER is an innovative, independent non-profit healthcare research organization dedicated to improving the application of evidence throughout the healthcare system.
-
ICER produces influential public reports evaluating the clinical effectiveness and value of new treatments, tests, and delivery system interventions.
-
These reports have strongly influenced US drug pricing policy and have been used by a wide variety of public and private insurers.
-
ICER convenes independent appraisal committee meetings to ensure that all perspectives are heard and that scientific and ethical values are addressed transparently.
-
ICER has become a leader in the methods of cost-effectiveness analysis within a broader health technology assessment framework.
-
ICER is known within the international HTA community as leaders in evaluating treatments for ultra-rare disorders and addressing distinctive assessment challenges of cell and gene therapies.